ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

ClinicalTrials.gov ID: NCT05283720

Public ClinicalTrials.gov record NCT05283720. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 10, 2026, 8:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma

Study identification

NCT ID
NCT05283720
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Genmab
Industry
Enrollment
496 participants

Conditions and interventions

Interventions

  • CC-99282 Drug
  • Cyclophosphamide Drug
  • Doxorubicin Hydrochloride [HCl] Drug
  • Epcoritamab Drug
  • Ibrutinib Drug
  • Lenalidomide Drug
  • Polatuzumab Vedotin Drug
  • Prednisone Drug
  • Rituximab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 13, 2022
Primary completion
Oct 31, 2032
Completion
Oct 31, 2032
Last update posted
May 5, 2026

2022 – 2032

United States locations

U.S. sites
18
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
The University of Arizona Cancer Center - North Campus /ID# 242219 Tucson Arizona 85719 Completed
Yale University School of Medicine /ID# 242089 New Haven Connecticut 06510 Recruiting
Christiana Care Health Service /ID# 242301 Newark Delaware 19713 Recruiting
Tampa General Hospital /ID# 246748 Tampa Florida 33606 Recruiting
Winship Cancer Institute of Emory University /ID# 242153 Atlanta Georgia 30322 Completed
University of Maryland, Baltimore /ID# 242218 Baltimore Maryland 21201 Recruiting
Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144 Kansas City Missouri 64114-4859 Completed
Northwell Health - Monter Cancer Center /ID# 245435 Lake Success New York 11042 Recruiting
Icahn School of Medicine at Mount Sinai /ID# 242123 New York New York 10029 Recruiting
Novant Health Presbyterian Medical Center /ID# 242148 Charlotte North Carolina 28204 Completed
East Carolina University - Brody School of Medicine /ID# 242506 Greenville North Carolina 27834 Recruiting
Novant Health Forsyth Medical Center /ID# 242198 Winston-Salem North Carolina 27103 Completed
Thomas Jefferson University Hospital /ID# 242077 Philadelphia Pennsylvania 19107 Completed
Fox Chase Cancer Center /ID# 242106 Philadelphia Pennsylvania 19111 Completed
Thompson Cancer Survival Ctr /ID# 242150 Knoxville Tennessee 37916 Completed
Joe Arrington Cancer Research /ID# 242226 Lubbock Texas 79410 Completed
Swedish Medical Center - Seattle /ID# 242269 Seattle Washington 98104 Recruiting
MultiCare Institute for Research & Innovation /ID# 242127 Tacoma Washington 98405 Completed

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05283720, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 5, 2026 · Synced May 10, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05283720 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →